Antiepileptic drug levels and side effects in man

Area of Science:

• Pharmacology
• Clinical Neurology
• Epilepsy Treatment

Background:

• Combined therapy with diphenylhydantoin (DPH), primidone, and phenobarbital is used for epilepsy.
• Monitoring drug serum levels is crucial for managing treatment efficacy and side effects.

Purpose of the Study:

• To investigate the correlation between serum drug levels and side effects in epileptic patients on combined therapy.
• To determine the optimal strategy for managing side effects associated with DPH in epilepsy treatment.

Main Methods:

• Analysis of serum drug levels (DPH, primidone, phenobarbital) in 22 hospitalized epileptic patients.
• Correlation of side effect incidence and clinical manifestation with serum DPH levels.
• Clinical observation of patient response to dosage adjustments and addition of phenobarbital.

Main Results:

• The number of side effects per patient directly correlated with serum diphenylhydantoin (DPH) levels.
• Reducing DPH dosage to manage side effects led to increased seizure frequency in one patient.
• Adding phenobarbital successfully reduced DPH serum levels, decreased side effects, and controlled seizures.

Conclusions:

• Diphenylhydantoin (DPH) serum levels are the primary determinant of side effects in combined epilepsy therapy.
• Adding phenobarbital appears to be a more effective strategy than reducing DPH dosage for managing side effects.
• Phenobarbital's potential to decrease DPH serum levels warrants further investigation for optimizing epilepsy management.